blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2387989

EP2387989 - Long - acting formulations of insulins [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.05.2015
Database last updated on 21.03.2026
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
SANOFI
54, rue La Boétie
75008 Paris / FR
[2014/29]
Former [2012/18]For all designated states
SANOFI
54 rue La Boétie
75008 Paris / FR
Former [2012/17]For all designated states
SANOFI
54, rue de la Boétie
75008 Paris / FR
Former [2011/47]For all designated states
SANOFI
174, Avenue de France
75013 Paris / FR
Inventor(s)01 / Becker, Reinhard, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
02 / Hahn, Annke, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
03 / Boderke, Peter, Dr.
Bockenheimer Strasse 3
65824 Schwalbach / DE
04 / Fuerst, Christiane, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
05 / Mueller, Werner, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
06 / Tertsch, Katrin, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
07 / Werner, Ulrich, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
08 / Loos, Petra, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
09 / Schoettle, Isabell
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
 [2014/28]
Former [2011/47]01 / Becker, Reinhard, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
02 / Hahn, Annke, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
03 / Boderke, Peter, Dr.
Bockenheimer Strasse 3
65824 Schwalbach / DE
04 / Fuerst, Christiane, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
05 / Mueller, Werner, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
06 / Tertsch, Katrin, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
07 / Werner, Ulrich, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
08 / Loos, Petra, Dr.
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[N/P]
Former [2012/47]Weiss, Wolfgang, et al
Weickmann & Weickmann Postfach 860820
81635 München / DE
Former [2011/47]Löwrick, Oliver, et al
Sanofi-Aventis Deutschland GmbH Patent- und Lizenzabteilung Industriepark Höchst Gebaüde K 801
65926 Frankfurt am Main / DE
Application number, filing date11166415.717.05.2011
[2011/47]
Priority number, dateEP2010030553219.05.2010         Original published format: EP 10305532
EP2010030578013.07.2010         Original published format: EP 10305780
EP2011030514010.02.2011         Original published format: EP 11305140
[2011/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2387989
Date:23.11.2011
Language:EN
[2011/47]
Type: A3 Search report 
No.:EP2387989
Date:18.04.2012
Language:EN
[2012/16]
Type: B1 Patent specification 
No.:EP2387989
Date:16.07.2014
Language:EN
[2014/29]
Search report(s)(Supplementary) European search report - dispatched on:EP20.03.2012
ClassificationIPC:A61K9/00, A61K38/28, A61K9/08
[2012/16]
CPC:
A61K38/28 (EP,KR,RU,US); A61K9/08 (EP,KR,US); A61K38/2278 (EP,US);
A61K38/26 (EP,US); A61K47/02 (EP,US); A61K47/10 (EP,US);
A61K47/26 (EP,US); A61K47/30 (KR); A61K9/0019 (EP,US);
A61P3/08 (EP); A61P3/10 (EP); A61P5/48 (EP);
A61P5/50 (EP) (-)
Former IPC [2011/47]A61K9/00, A61K38/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2011/47]
Extension statesBA18.10.2012
ME18.10.2012
TitleGerman:Formulierungen mit Langzeitwirkung von Insulinen[2011/47]
English:Long - acting formulations of insulins[2011/47]
French:Formulations longue durée d'insulines[2011/47]
Examination procedure04.10.2012Amendment by applicant (claims and/or description)
18.10.2012Examination requested  [2012/48]
30.11.2012Despatch of a communication from the examining division (Time limit: M06)
12.04.2013Reply to a communication from the examining division
24.01.2014Communication of intention to grant the patent
24.04.2014Fee for grant paid
24.04.2014Fee for publishing/printing paid
24.04.2014Receipt of the translation of the claim(s)
Divisional application(s)EP14166877.2  / EP2781212
EP18161680.6  / EP3424491
EP19184732.6  / EP3636250
EP20199940.6  / EP3824876
EP23157670.3
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.11.2012
Opposition(s)17.04.2015No opposition filed within time limit [2015/26]
Fees paidRenewal fee
10.05.2013Renewal fee patent year 03
27.03.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL16.07.2014
MC16.07.2014
MK16.07.2014
SM16.07.2014
IS16.11.2014
[2018/46]
Former [2018/31]MC16.07.2014
MK16.07.2014
SM16.07.2014
IS16.11.2014
Former [2017/38]MC16.07.2014
SM16.07.2014
IS16.11.2014
Former [2016/06]MC16.07.2014
IS16.11.2014
Former [2015/12]IS16.11.2014
Documents cited:Search[IA] US2004048783  (BRUNNER-SCHWARZ ANETTE et al.)
 [A] US2009175840  (KASHYAP NANDINI et al.)
 [A] WO2004064862  (AVENTIS PHARMA INC et al.)
 [I] US2004235710  (DEFELIPPIS MICHAEL ROSARIO et al.)
 [A] WO2008013938  (NEKTAR THERAPEUTICS et al.) [A] 1-29 * claims 1-3 *
 [IA]   SECNIK BOYE KRISTINA ET AL: "Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes", HEALTH AND QUALITY OF LIFE OUTCOMES, BIOMED CENTRAL, LONDON, GB, vol. 4, no. 1, 11 October 2006 (2006-10-11), pages 80, XP021024604, ISSN: 1477-7525, DOI: 10.1186/1477-7525-4-80 [A] 5,17-28

DOI:   http://dx.doi.org/10.1186/1477-7525-4-80
 [A]   HOE 901/2004 STUDY INVESTIGATORS GROUP ED - HOE 901/2004 STUDY INVESTIGATORS GROUP: "Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients", SAFETY AND EFFICACY OF INSULIN GLARGINE (HOE 901) VERSUS NPH INSULIN IN COMBINATION WITH ORAL TREATMENT IN TYPE 2 DIABETIC PATIENTS,, vol. 20, 2003, pages 545 - 551, XP002671079

DOI:   http://dx.doi.org/10.1046/j.1464-5491.2003.00999.x
by applicantWO2008013938
   "Diabetes Care", vol. 21, 1998, AMERICAN DIABETIC ASSOCIATION, article "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus", pages: 5 - 19
   SAMSPON HA, MUNOZ-FURLONG A, CAMPBELL RL ET AL.: "Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 117, no. 2, 2006, pages 391 - 397
   GOUGH K, HUTCHISON M, KEENE 0 ET AL.: "Assessment of dose proportionality: report from the pharmaceutical industry", DRUG INFORMATION JOURNAL, vol. 29, 1995, pages 1039 - 1048
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.